Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice

Gastroenterology

Volumn 124, Issue 2, 2003, Pages 361-367

  Osawa, Emi ^a   Nakajima, Atsushi ^a   Wada, Koichiro ^b   Ishimine, Satoko ^a   Fujisawa, Nobutaka ^a   Kawamori, Toshihiko ^c   Matsuhashi, Nobuyuki ^d   Kadowaki, Takashi ^d   Ochiai, Masako ^c   Sekihara, Hisahiko ^a   Nakagama, Hitoshi ^c  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER MODEL; CELL DIFFERENTIATION; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL;

EID: 0037309496     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2003.50067     Document Type: Article

References (24)

1. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000;21:525-530.
2. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998;90:1371-1388.
3. Lambe KG, Tugwood JD. A human PPARγ is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem 1996;239:1-7.
4. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-Δ 12, 14-prostaglandin J2 is a ligand of the adipocyte determination factor PPARγ. Cell 1995;83:803-813.
5. Lefebvre AM, Auwerx J. PPARγ is induced during differentiation of colon epithelium cells. J Endocrinol 1999;162:331-340.
6. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Christopher D, Fletcher M, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM. Terminal differentiation of human liposarcoma cells induced by ligands for PPARγ and the retinoid X receptor. Proc Natl Acad Sci U S A 1997;94:237-241.
7. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of PPARγ in non small cell lung cancer. Cancer Res 2000;60:1129-1138.
8. Takahashi N, Kohgo Y. Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999;455:135-139.
9. Min/+mice. Nat Med 1998;4:1053-1057.
10. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM. Activation of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med 1998;4:1058-1061.
11. Sarraf P, Mueller E, Jones D, Fletcher C, Spiegelman BM. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998;4:1046-1052.
12. Gupta RA, Brockman JA, Sarraf P, Willson TM, DuBois RN. Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem 2001;276:29681-29687.
13. Bird RP. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 1995;93:55-71.
14. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998;339:1277-1284.
15. McLellan EA, Bird RP. Aberrant crypts: potential preneoplastic lesions in the murine colon. Cancer Res 1988;48:6187-6192.
16. Konstantakos AK, Siu IM, Pretlow TG, Stellato TA, Pretlow TP. Human aberrant crypt foci with carcinoma in situ from a patient with sporadic colon cancer. Gastroenterology 1996;111:772-777.
17. Takahashi M, Fukutake M, Sugimura T, Wakabayashi K. Suppression of azoxymethane-induced rat colon carcinoma development by a fish oil component, docosahexaenoic acid (DHA). Carcinogenesis 1997;18:1337-1342.
18. Pozharisski KM. Tumors of the intestines. In: Turusov VS, Mohr V, eds. Pathology of tumors in laboratory animals. Lyon, France; IARC Scientific Publications, 1990;99:159-198.
19. INK4C in troglitazone-induced cellcycle arrest in human hepatoma cell lines. Hepatology 2001;33:1087-1097.
20. Wada K, Nakajima A, Blumberg RS. PPARγ and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohns disease. Trends Mol Med 2001;7:329-333.
21. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPARγ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001;7:48-52.
22. Wang YL, Frauwirth KA, Rangwala SM, Lazar MA, Thompson CB. Thiazolidinedione activation of peroxisome proliferator-activated receptor γ can enhance mitochondrial potential and promote cell survival. J Biol Chem 2002;277:31781-31788.
23. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res 2001;61:6213-6218.
24. Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A, Hosokawa M. Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001;61:2424-2428.